HAOXI and Eaglepoint AI Partner to Launch AI Health Platform in China
HAOXI Health Technology and Eaglepoint AI have signed a three-year strategic agreement to develop an AI-powered health management platform for the Chinese market. The collaboration will leverage Eaglepoint’s Aquila data engine and HAOXI’s marketing reach to launch the 'AI Digital Health Manager' SaaS system.
Beat this week
Last 7 days · Market Trends
Impact 5.7/10 (+0.3 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 22 percentage points.
This story sits in Market Trends — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Startup briefing
Key takeaways
- HAOXI Health Technology and Eaglepoint AI have signed a three-year strategic agreement to develop an AI-powered health management platform for the Chinese market.
- The collaboration will leverage Eaglepoint’s Aquila data engine and HAOXI’s marketing reach to launch the 'AI Digital Health Manager' SaaS system.
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Three-year strategic cooperation agreement signed between HAOXI and Eaglepoint AI.
- 2First deployment of the Aquila data engine in a high-growth health management scenario.
- 3Launch of 'AI Digital Health Manager' SaaS targeting the 'sub-healthy' population in China.
- 4HAOXI provides marketing networks and commercial conversion support.
- 5Eaglepoint AI manages model training, data security, and algorithm iteration.
- 6Focus areas include intelligent nutrition, chronic disease risk assessment, and digital therapeutics.
Who's Affected
Analysis
The partnership between HAOXI Health Technology and Eaglepoint AI represents a significant move into the burgeoning AI-driven healthcare market in China. By combining HAOXI’s established marketing infrastructure with Eaglepoint’s advanced AI capabilities, the two companies aim to address the growing demand for personalized, preventive health management. This three-year agreement is not merely a technical integration but a strategic pivot for HAOXI as it seeks to capitalize on the AI-plus-healthcare trend that is currently reshaping the venture capital landscape in Asia.
At the heart of this collaboration is the deployment of Eaglepoint AI’s proprietary Aquila data engine and its multimodal model evaluation system. This marks the first time these specific technologies have been applied to a high-growth health management scenario, signaling a diversification strategy for Eaglepoint's parent company, Global Mofy AI. The technical focus will be on model training, algorithm iteration, and, crucially, data security compliance—a vital component given China’s stringent regulatory environment regarding health data. The partnership aims to bridge the gap between raw AI processing power and practical, consumer-facing health applications.
At the heart of this collaboration is the deployment of Eaglepoint AI’s proprietary Aquila data engine and its multimodal model evaluation system.
The initial output of this partnership will be the AI Digital Health Manager, a SaaS platform designed to target the sub-healthy population. This demographic, characterized by individuals who do not have a diagnosed disease but exhibit low vitality or chronic fatigue, represents a massive and underserved market in urban China. The platform will offer intelligent nutrition advice, chronic disease risk assessments, and digital therapeutics, moving beyond simple tracking to provide actionable, AI-generated health interventions. By focusing on preventive care, the partners are positioning themselves at the forefront of a shift from reactive medicine to proactive wellness management.
What to Watch
For venture investors and industry analysts, this partnership highlights a broader trend: the transition of AI from general-purpose applications to highly specialized vertical solutions. While many AI startups struggle with user acquisition, the HAOXI-Eaglepoint model solves this by pairing a technical provider with a partner that possesses an existing commercial network. This tech-plus-channel approach reduces the time-to-market and provides a clearer path to monetization through SaaS subscriptions and health service conversions. It also provides a blueprint for how NASDAQ-listed micro-cap companies can pool resources to compete with larger tech conglomerates in the AI space.
Looking ahead, the success of this venture will depend on the efficacy of the Aquila engine in processing complex medical and lifestyle data. If the AI Digital Health Manager can demonstrate measurable improvements in user health outcomes, it could set a precedent for how AI is integrated into China’s public and private health sectors. Investors should monitor the first-phase rollout for user retention metrics and any further regulatory filings that might indicate a deeper merger or acquisition interest between the two entities. The three-year window provides ample time for the partners to iterate on their multimodal models and establish a dominant position in the digital health manager niche.
Timeline
Timeline
Strategic R&D
Ongoing joint commitment of R&D, data, and channel resources for AI health management.
Partnership Announcement
HAOXI Health and Eaglepoint AI sign a three-year strategic cooperation agreement.
Phase 1 Launch
Initial rollout of the 'AI Digital Health Manager' SaaS system targeting sub-healthy demographics.
Cite This Page
"HAOXI and Eaglepoint AI Partner to Launch AI Health Platform in China." Startup Intelligence Brief, March 4, 2026. https://getstartupbrief.com/story/haoxi-eaglepoint-ai-health-partnership-china
How we covered this story
Every story in our startup coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the startup space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled startup-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |